Synthetic Biology: Immunotherapy by Design

Annual Review of Biomedical Engineering

Volumn 20, Issue , 2018, Pages 95-118

  Brenner, Matthew J ^a   Cho, Jang Hwan ^a   Wong, Nicole M L ^a   Wong, Wilson W ^a  

^a Boston University   (United States)

Author keywords

autoimmune disease; cancer; cellular immunotherapy; genetic circuits; infectious disease; synthetic biology

Indexed keywords

BIOLOGY; T-CELLS;

AUTOIMMUNE DISEASE; CANCER; CELLULAR IMMUNOTHERAPY; GENETIC CIRCUITS; INFECTIOUS DISEASE; SYNTHETIC BIOLOGY;

DISEASES;

ALLOIMMUNITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MYCOSIS; NONHUMAN; REVIEW; SAFETY; SYNTHETIC BIOLOGY; T LYMPHOCYTE; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; IMMUNOLOGY; NEOPLASM; PATIENT SAFETY; PROCEDURES;

IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASES; CELL- AND TISSUE-BASED THERAPY; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MYCOSES; NEOPLASMS; PATIENT SAFETY; SYNTHETIC BIOLOGY; T-LYMPHOCYTES;

EID: 85042474325     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-062117-121147     Document Type: Review

References (150)

1. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252-64
2. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, et al. 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207-11
3. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463-69
4. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, et al. 2015. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21:914-21
5. Sadelain M, Brentjens R, Riviere I. 2013. The basic principles of chimeric antigen receptor design. Cancer Discov. 3:388-98
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365:725-33
7. Davila ML, Riviere I,Wang X, Bartido S, Park J, et al. 2014. Efficacy and toxicitymanagement of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6:224ra25
8. Gardner TS, Cantor CR, Collins JJ. 2000. Construction of a genetic toggle switch in Escherichia coli. Nature 403:339-42
9. Elowitz MB, Leibler S. 2000. A synthetic oscillatory network of transcriptional regulators. Nature 403:335-38
10. Mondragon-Palomino O, Danino T, Selimkhanov J, Tsimring L, Hasty J. 2011. Entrainment of a population of synthetic genetic oscillators. Science 333:1315-19
11. Weinberg BH, Pham NTH, Caraballo LD, Lozanoski T, Engel A, et al. 2017. Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. Nat. Biotechnol. 35:453-62
12. Siuti P, Yazbek J, Lu TK. 2013. Synthetic circuits integrating logic and memory in living cells. Nat. Biotechnol. 31:448-52
13. Guinn M, Bleris L. 2014. Biological 2-input decoder circuit in human cells. ACS Synth. Biol. 3:627-33
14. Wei P,Wong WW, Park JS, Corcoran EE, Peisajovich SG, et al. 2012. Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. Nature 488:384-88
15. Becskei A, Serrano L. 2000. Engineering stability in gene networks by autoregulation. Nature 405:590-93
16. Xie M, Ye H, Wang H, Charpin-El Hamri G, Lormeau C, et al. 2016. β-cell-mimetic designer cells provide closed-loop glycemic control. Science 354:1296-301
17. Atsumi S, Hanai T, Liao JC. 2008. Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels. Nature 451:86-89
18. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, et al. 2006. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440:940-43
19. DeLoacheWC, Russ ZN, Narcross L, Gonzales AM, Martin VJ, Dueber JE. 2015. An enzyme-coupled biosensor enables (S)-reticuline production in yeast from glucose. Nat. Chem. Biol. 11:465-71
20. Galanie S, Thodey K, Trenchard IJ, Filsinger Interrante M, Smolke CD. 2015. Complete biosynthesis of opioids in yeast. Science 349:1095-100
21. Ajikumar PK, Xiao WH, Tyo KE,Wang Y, Simeon F, et al. 2010. Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science 330:70-74
22. YimH,Haselbeck R, NiuW, Pujol-BaxleyC, Burgard A, et al. 2011. Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol. Nat. Chem. Biol. 7:445-52
23. Choi SY, Park SJ, Kim WJ, Yang JE, Lee H, et al. 2016. One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli. Nat. Biotechnol. 34:435-40
24. Chappell J, Takahashi MK, Lucks JB. 2015. Creating small transcription activating RNAs. Nat. Chem. Biol. 11:214-20
25. Green AA, Silver PA, Collins JJ, Yin P. 2014. Toehold switches: de-novo-designed regulators of gene expression. Cell 159:925-39
26. Bonnet J, Yin P, Ortiz ME, Subsoontorn P, Endy D. 2013. Amplifying genetic logic gates. Science 340:599-603
27. Khalil AS, Lu TK, Bashor CJ, Ramirez CL, Pyenson NC, et al. 2012. A synthetic biology framework for programming eukaryotic transcription functions. Cell 150:647-58
28. Schwarz KA, Daringer NM, Dolberg TB, Leonard JN. 2017. Rewiring human cellular input-output using modular extracellular sensors. Nat. Chem. Biol. 13:202-9
29. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, et al. 2016. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164:780-91
30. Gibson DG, YoungL,ChuangRY, Venter JC,HutchisonCA3rd, SmithHO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6:343-45
31. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S. 2011. A modular cloning system for standardized assembly of multigene constructs. PLOS ONE 6:e16765
32. Kong DS, Thorsen TA, Babb J, Wick ST, Gam JJ, et al. 2017. Open-source, community-driven microfluidics with Metafluidics. Nat. Biotechnol. 35:523-29
33. GajT,Gersbach CA, BarbasCF 3rd. 2013. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31:397-405
34. Woodsworth DJ, Holt RA. 2017. Cell-based therapeutics: making a Faustian pact with biology. Trends Mol. Med. 23:104-15
35. Nielsen AA, Der BS, Shin J, Vaidyanathan P, Paralanov V, et al. 2016. Genetic circuit design automation. Science 352:aac7341
36. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, et al. 1988. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1676-80
37. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106-15
38. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, et al. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66:10995-1004
39. Wang J, Jensen M, Lin Y, Sui X, Chen E, et al. 2007. Optimizing adoptive polyclonalTcell immunotherapy of lymphomas, using a chimericTcell receptor possessing CD28 andCD137 costimulatory domains. Hum. Gene Ther. 18:712-25
40. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-20
41. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. 2010. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18:666-68
42. Sadelain M, Riviere I, Riddell S. 2017. Therapeutic T cell engineering. Nature 545:423-31
43. LimWA, June CH. 2017. The principles of engineering immune cells to treat cancer. Cell 168:724-40
44. RobertsMR, Qin L, Zhang D, Smith DH, Tran AC, et al. 1994. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-89
45. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, et al. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5:788-97
46. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, et al. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4:132ra53
47. Liu B, Zou F, Lu L, Chen C, He D, et al. 2016. Chimeric antigen receptor T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4+ T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy. J. Virol. 90:9712-24
48. AliA, Kitchen SG,Chen IS,NgHL,Zack JA, Yang OO.2016. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J. Virol. 90:6999-7006
49. Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, et al. 2017. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25:570-79
50. Descours B, Petitjean G, L opez-Zaragoza JL, Bruel T, Raffel R, et al. 2017. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543:564-67
51. Kriengkauykiat J, Ito JI, Dadwal SS. 2011. Epidemiology and treatment approaches in management of invasive fungal infections. Clin. Epidemiol. 3:175-91
52. Armstrong-James D, Harrison TS. 2012. Immunotherapy for fungal infections. Curr. Opin. Microbiol. 15:434-39
53. Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, et al. 2010. Exogenous interferon-γ immunotherapy for invasive fungal infections in kidney transplant patients. Am. J. Transplant. 10:1796-803
54. Safdar A, RodriguezG,OhmagariN,KontoyiannisDP, Rolston KV, et al. 2005. The safety of interferon-γ-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103:731-39
55. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, et al. 2012. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 26:1105-13
56. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, et al. 2009. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. PNAS 106:2818-23
57. Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, et al. 2010. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect.Dis. 202:633-37
58. Louie A, Stein DS, Zack JZ, Liu W, Conde H, et al. 2011. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrob. Agents Chemother. 55:3295-304
59. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, et al. 2003. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102:3807-14
60. Ang AL, Linn YC. 2011. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era-experience from an adult haematology unit in Singapore. Transfus. Med. 21:13-24
61. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, et al. 2004. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 101:2859-65
62. Lin L, Ibrahim AS, Baquir B, Fu Y, ApplebaumD, et al. 2010. Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J. Infect. Dis. 201:1708-17
63. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, et al. 2005. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106:4397-406
64. Gaundar SS, Clancy L, Blyth E, Meyer W, Gottlieb DJ. 2012. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy 14:1119-30
65. Bacher P, Jochheim-Richter A,Mockel-TenbrinkN, Kniemeyer O, Wingenfeld E, et al. 2015. Clinicalscale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. Cytotherapy 17:1396-405
66. Papadopoulou A, Kaloyannidis P, Yannaki E, Cruz CR. 2016. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: progress and challenges. Crit. Rev. Oncol. Hematol. 98:62-72
67. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, et al. 2014. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. PNAS 111:10660-65
68. Parida SK, Poiret T, Zhenjiang L, Meng Q, Heyckendorf J, et al. 2015. T-cell therapy: options for infectious diseases. Clin. Infect. Dis. 61(Suppl. 3):S217-24
69. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. 2004. Efficacy of Bcell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J.Med. 350:2572-81
70. Tchorbanov AI, Voynova EN, MihaylovaNM, Todorov TA,NikolovaM, et al. 2007. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 37:3587-96
71. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, et al. 2016. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179-84
72. Elinav E, Adam N, Waks T, Eshhar Z. 2009. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 136:1721-31
73. Taylor PA, Lees CJ, Blazar BR. 2002. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99:3493-99
74. MacDonald KG,HoeppliRE, HuangQ,Gillies J,LucianiDS, et al. 2016. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Investig. 126:1413-24
75. Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, et al. 2017. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35:765-72
76. KimYC,Zhang AH, SuY,Rieder SA, Rossi RJ, et al. 2015. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T-and B-cell responses. Blood 125:1107-15
77. Yoon J, Schmidt A, Zhang AH, Konigs C, Kim YC, Scott DW. 2017. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T-and B-cell responses to FVIII. Blood 129:238-45
78. McLaughlin KA, Richardson CC, Ravishankar A, Brigatti C, Liberati D, et al. 2016. Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes 65:1690-98
79. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18:843-51
80. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, et al. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517-28
81. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36:133-51
82. Deo SS, Gottlieb DJ. 2015. Adoptive T-cell therapy for fungal infections in haematology patients. Clin. Transl. Immunol. 4:e40
83. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, et al. 2015. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J. Virol. 89:6685-94
84. Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, et al. 2011. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res. 71:7176-86
85. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. 1994. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3 enhancer. PNAS 91:6496-500
86. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, et al. 2006. A2A adenosine receptor protects tumors from antitumor T cells. PNAS 103:13132-37
87. Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. 2012. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol. Immunother. 61:917-26
88. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, et al. 2016. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45:374-88
89. Coussens LM,Werb Z. 2002. Inflammation and cancer. Nature 420:860-67
90. Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, et al. 2009. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 69:4800-9
91. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1:54-67
92. Chen X, Takemoto Y, Deng H, Middelhoff M, Friedman RA, et al. 2017. Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer. Oncoimmunology 6:e1290034
93. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24:5373-80
94. Wang X, Riviere I. 2016. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3:16015
95. Lienert F, Lohmueller JJ, Garg A, Silver PA. 2014. Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 15:95-107
96. Rinaudo K, Bleris L, Maddamsetti R, Subramanian S, Weiss R, Benenson Y. 2007. A universal RNAibased logic evaluator that operates in mammalian cells. Nat. Biotechnol. 25:795-801
97. Xie Z, Liu SJ, Bleris L, Benenson Y. 2010. Logic integration of mRNA signals by an RNAi-based molecular computer. Nucleic Acids Res. 38:2692-701
98. NishimuraK, FukagawaT,TakisawaH, KakimotoT, KanemakiM. 2009. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. Methods 6:917-22
99. Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, et al. 2015. Tunable and reversible drug control of protein production via a self-excising degron. Nat. Chem. Biol. 11:713-20
100. Grimley JS, Chen DA, Banaszynski LA, Wandless TJ. 2008. Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains. Bioorg. Med. Chem. Lett. 18:759-61
101. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. 2015. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350:aab4077
102. Miyamoto T, DeRose R, Suarez A, Ueno T, Chen M, et al. 2012. Rapid and orthogonal logic gating with a gibberellin-induced dimerization system. Nat. Chem. Biol. 8:465-70
103. Taslimi A, Zoltowski B, Miranda JG, Pathak GP, Hughes RM, Tucker CL. 2016. Optimized secondgeneration CRY2-CIB dimerizers and photoactivatable Cre recombinase. Nat. Chem. Biol. 12:425-30
104. Inoue T, Heo WD, Grimley JS, Wandless TJ, Meyer T. 2005. An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways. Nat. Methods 2:415-18
105. Levskaya A, Weiner OD, Lim WA, Voigt CA. 2009. Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 461:997-1001
106. Polstein LR, Gersbach CA. 2015. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat. Chem. Biol. 11:198-200
107. Niopek D, Benzinger D, Roensch J, Draebing T, Wehler P, et al. 2014. Engineering light-inducible nuclear localization signals for precise spatiotemporal control of protein dynamics in living cells. Nat. Commun. 5:4404
108. Guntas G, Hallett RA, Zimmerman SP, Williams T, Yumerefendi H, et al. 2015. Engineering an improved light-induced dimer (iLID) for controlling the localization and activity of signaling proteins. PNAS 112:112-17
109. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracyclineresponsive promoters. PNAS 89:5547-51
110. Brown M, Figge J, Hansen U, Wright C, Jeang KT, et al. 1987. lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. Cell 49:603-12
111. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, et al. 2008. Rapid "opensource" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol. Cell 31:294-301
112. Keung AJ, Bashor CJ, Kiriakov S, Collins JJ, Khalil AS. 2014. Using targeted chromatin regulators to engineer combinatorial and spatial transcriptional regulation. Cell 158:110-20
113. Morbitzer R, Romer P, Boch J, Lahaye T. 2010. Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors. PNAS 107:21617-22
114. Garg A, Lohmueller JJ, Silver PA,Armel TZ. 2012. Engineering syntheticTALeffectors with orthogonal target sites. Nucleic Acids Res. 40:7584-95
115. Reyon D, Khayter C, Regan MR, Joung JK, Sander JD. 2012. Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly. Curr. Protoc. Mol. Biol. 100:12.15.1-12.15.14
116. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, et al. 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173-83
117. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. 2013. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10:977-79
118. Perez-Pinera P, Kocak DD, VockleyCM, AdlerAF, KabadiAM, et al. 2013. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 10:973-76
119. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. 2013. RNA-programmed genome editing in human cells. eLife 2:e00471
120. Bibikova M, Beumer K, Trautman JK, Carroll D. 2003. Enhancing gene targeting with designed zinc finger nucleases. Science 300:764
121. Eyquem J,Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, et al. 2017. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543:113-17
122. Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, et al. 2008. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 5:673-78
123. Barnea G, Strapps W, Herrada G, Berman Y, Ong J, et al. 2008. The genetic design of signaling cascades to record receptor activation. PNAS 105:64-69
124. Roybal KT,Williams JZ, Morsut L, Rupp LJ, Kolinko I, et al. 2016. EngineeringTcells with customized therapeutic response programs using synthetic Notch receptors. Cell 167:419-32
125. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, et al. 2016. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770-79
126. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, et al. 2013. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21:2087-101
127. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, et al. 2013. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2:e105
128. Wu CY, Rupp LJ, Roybal KT, Lim WA. 2015. Synthetic biology approaches to engineer T cells. Curr. Opin. Immunol. 35:123-30
129. RodgersDT, MazagovaM,Hampton EN, Cao Y, RamadossNS, et al. 2016. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. PNAS 113:E459-68
130. MaJS, Kim JY, Kazane SA, Choi SH, Yun HY, et al. 2016. Versatile strategy for controlling the specificity and activity of engineered T cells. PNAS 113:E450-58
131. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, et al. 2012. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18:6436-45
132. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, et al. 2012. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72:1844-52
133. Fedorov VD, Themeli M, Sadelain M. 2013. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5:215ra172
134. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673-83
135. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, et al. 2005. An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247-54
136. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, et al. 2010. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16:5458-68
137. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, et al. 2011. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17:4719-30
138. Xu Y, Hyun YM, Lim K, Lee H, Cummings RJ, et al. 2014. Optogenetic control of chemokine receptor signal and T-cell migration. PNAS 111:6371-76
139. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, et al. 2015. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21:524-29
140. Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, et al. 2013. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 20:575-80
141. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, et al. 2014. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22:1211-20
142. ProsserME, Brown CE, Shami AF, Forman SJ, Jensen MC. 2012. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51:263-72
143. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, et al. 2009. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther. 16:883-91
144. Zhang L,Morgan RA, Beane JD, Zheng Z,Dudley ME, et al. 2015. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy ofmetastatic melanoma. Clin. Cancer Res. 21:2278-88
145. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, et al. 2017. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9:eaaj2013
146. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR. 2016. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat. Biotechnol. 34:430-34
147. Kwong GA, vonMaltzahn G,Murugappan G, Abudayyeh O, Mo S, et al. 2013. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31:63-70
148. Kwon EJ, Dudani JS, Bhatia SN. 2017. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat. Biomed. Eng. 1:0054
149. Baker DJ, Childs BG, DurikM,WijersME, Sieben CJ, et al. 2016. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530:184-89
150. Chang J,Wang Y, Shao L, Laberge RM,Demaria M, et al. 2016. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22:78-83